Morquio A Syndrome Clinical Trial
Official title:
A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA
The Expanded Access Program (EAP) is an open-label, multicenter program to:
1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA)
access to BMN 110 until commercial product is available
2. Collect additional information on the safety and tolerability of BMN 110 administration
in patients with MPS IVA
Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every
week during the program.
n/a
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05845749 -
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI
|
Phase 1/Phase 2 | |
| Completed |
NCT02294877 -
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
|
||
| Completed |
NCT01961518 -
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
|
N/A | |
| Completed |
NCT01515956 -
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
|
Phase 2 | |
| Recruiting |
NCT05284006 -
Non-invasive Functional Assessment and Pathogenesis of Morquio A
|
||
| Completed |
NCT01415427 -
Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
|
Phase 3 | |
| Recruiting |
NCT04532047 -
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
|
Phase 1 | |
| Completed |
NCT01920828 -
Gait Analysis in MPS IVA
|
||
| Terminated |
NCT01697319 -
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
|
Phase 2 | |
| Terminated |
NCT01609062 -
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
|
Phase 2 |